11,381
Total Claims
$1.9M
Drug Cost
1,367
Beneficiaries
$1,362
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
-11%
Cost per patient vs peers
$1,362 vs $1,524 avg
+45%
Brand preference vs peers
19.8% vs 13.7% avg
Brand vs Generic
80% generic
Brand: 2,248 claims · $1.6M
Generic: 9,133 claims · $214K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 886 | $686K |
| Rivaroxaban | 476 | $422K |
| Dronedarone Hcl | 76 | $109K |
| Sacubitril/Valsartan | 105 | $97K |
| Evolocumab | 109 | $74K |
| Empagliflozin | 97 | $62K |
| Dapagliflozin Propanediol | 90 | $58K |
| Alirocumab | 52 | $38K |
| Ranolazine | 331 | $34K |
| Azilsartan Med/Chlorthalidone | 90 | $27K |
| Nebivolol Hcl | 235 | $25K |
| Ticagrelor | 31 | $19K |
| Icosapent Ethyl | 45 | $17K |
| Metoprolol Succinate | 812 | $11K |
| Losartan Potassium | 786 | $9,603 |
Prescribing Profile
73
Unique Drugs
$1.3M
Patient Profile
75
Avg Age
53%
Female
1.43
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data